Constellation Pharmaceuticals, Inc. (CNST) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Constellation Pharmaceuticals, Inc. (CNST) trades at $33.99 with AI Score 47/100 (Grade C). Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancers with unmet medical needs. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for CNST: CNST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNST against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNST: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Constellation Pharmaceuticals, Inc. (CNST) Healthcare & Pipeline Overview
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in innovative cancer therapies, with a focus on addressing unmet medical needs through unique product candidates, including CPI-0610 and CPI-1205, currently in advanced clinical trials.
What Is the Investment Thesis for CNST?
Constellation Pharmaceuticals, Inc. is poised for growth driven by its innovative pipeline and strategic focus on unmet medical needs in oncology. The lead candidate, CPI-0610, is in Phase II trials, with potential market entry expected in the next few years, targeting a significant patient population suffering from myelofibrosis. CPI-1205's ongoing Phase Ib/II trials for metastatic castration-resistant prostate cancer also represent a substantial opportunity, given the increasing prevalence of this condition. The company's unique focus on epigenetic therapies could offer competitive advantages, particularly as the market for cancer therapeutics continues to expand, projected to reach $200 billion by 2026. However, investors may want to evaluate the inherent risks associated with clinical trials, including regulatory hurdles and the potential for trial failures, which could impact timelines and financial performance.
Based on FMP financials and quantitative analysis
CNST Key Highlights
Lead candidate CPI-0610 in Phase II trials for myelofibrosis, targeting a significant market.
- CPI-1205 in Phase Ib/II trials for metastatic castration-resistant prostate cancer, addressing a growing patient demographic.
- No dividend yield, indicating a focus on reinvestment into clinical development.
- Beta of 2.58, reflecting higher volatility compared to the market.
- 154 employees dedicated to advancing innovative cancer therapies.
Who Are CNST's Competitors?
CNST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FGEN FibroGen, Inc. | $9.07 | -1.63% | $36.7M | 46 |
| CLDX Celldex Therapeutics, Inc. | $39.94 | -4.22% | $2.66B | — |
| TGTX TG Therapeutics, Inc. | $50.56 | -2.19% | $7.74B | 65 |
| KPTI Karyopharm Therapeutics Inc. | $1.82 | -9.00% | $41.3M | — |
| XLRN Acceleron Pharma Inc. | $178.75 | +0.00% | 63 | |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNST's Key Strengths?
Strong pipeline with multiple candidates in advanced clinical trials.
- Expertise in epigenetic modulation provides a competitive edge.
- Focus on unmet medical needs in oncology aligns with market demand.
- Experienced leadership team with a track record in biopharmaceuticals.
What Are CNST's Weaknesses?
Clinical-stage status means no current revenue generation.
- Dependence on successful trial outcomes for future growth.
- Limited market presence compared to larger biopharmaceutical companies.
- High operational costs associated with clinical trials and R&D.
What Could Drive CNST Stock Higher?
CNST catalyst: Results from Phase II trials of CPI-0610 expected in the next 12 months, which could significantly impact market perception.
- CPI-1205 is currently in Phase Ib/II trials, with data anticipated to provide insights into its efficacy for metastatic castration-resistant prostate cancer.
- Potential partnerships with larger pharmaceutical companies to enhance development capabilities and market reach.
- Continuous progress in the clinical development of CPI-0209 for solid tumors, with updates expected in the near future.
- Regulatory submissions anticipated based on successful trial outcomes, paving the way for potential product launches.
What Are the Key Risks for CNST?
Negative return on equity (-33.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Regulatory challenges could arise, delaying product approvals and impacting timelines.
- The high cost of clinical trials may strain financial resources and affect operational sustainability.
- Competition from other biopharmaceutical companies could limit market share and pricing power.
- Clinical trial failures pose a significant risk to the advancement of product candidates and overall valuation.
What Are the Growth Opportunities for CNST?
- Growth opportunity 1: The global cancer therapeutics market is projected to reach $200 billion by 2026, driven by rising cancer incidence and demand for innovative treatments. Constellation's focus on myelofibrosis and metastatic castration-resistant prostate cancer positions it to capture significant market share as its lead candidates advance through clinical trials, potentially leading to product launches within the next few years.
- Growth opportunity 2: Constellation Pharmaceuticals is exploring additional indications for its existing pipeline, particularly in solid tumors with CPI-0209. As the company progresses through clinical trials, it can leverage its expertise in epigenetic modulation to expand its therapeutic offerings, tapping into a market that is increasingly seeking novel treatment options.
- Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could enhance Constellation's research capabilities and accelerate the development of its product candidates. Collaborations can provide access to additional resources, expertise, and distribution networks, facilitating faster market entry and broader reach for its therapies.
- Growth opportunity 4: The increasing focus on personalized medicine and targeted therapies in oncology presents an opportunity for Constellation to differentiate its products. By emphasizing the unique mechanisms of action of its candidates, the company can appeal to healthcare providers and patients seeking tailored treatment options, potentially improving adoption rates.
- Growth opportunity 5: The company may explore international markets as it advances its clinical programs. Expanding its geographic reach could unlock new revenue streams, particularly in regions with high unmet medical needs for cancer therapies, allowing Constellation to diversify its market presence and mitigate risks associated with reliance on domestic sales.
What Threats Does CNST Face?
- Regulatory hurdles could delay product approvals and market entry.
- Intense competition from other biopharmaceutical companies in oncology.
- Market volatility and investor sentiment can impact funding opportunities.
- Risk of clinical trial failures affecting company valuation and prospects.
What Are CNST's Competitive Advantages?
- Unique focus on epigenetic therapies differentiates Constellation from competitors.
- Strong pipeline of clinical-stage product candidates with potential for significant market impact.
- Expertise in addressing unmet medical needs in oncology enhances credibility.
- Collaborative partnerships can provide resources and enhance research capabilities.
- Intellectual property portfolio protects innovations and provides competitive advantages.
What Does CNST Do?
Founded in 2008, Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was initially established as Epigenetix, Inc. before rebranding to its current name in March 2008. Constellation is dedicated to discovering and developing therapeutics aimed at treating serious unmet medical needs, particularly in oncology. Its lead product candidate, CPI-0610, is currently undergoing Phase II clinical trials for the treatment of myelofibrosis in combination with ruxolitinib, a well-known JAK inhibitor. Additionally, the company is advancing CPI-1205, which is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer, utilized in combination with androgen receptor signaling inhibitors. Another promising candidate, CPI-0209, is in the Phase I dose escalation portion of a Phase I/II clinical trial targeting solid tumors. With a dedicated workforce of 154 employees, Constellation Pharmaceuticals is positioned to make significant contributions to the biopharmaceutical landscape, particularly in the realm of cancer therapeutics. The company's innovative approach to drug development, focusing on epigenetic modulation and the treatment of cancers associated with abnormal gene expression or drug resistance, sets it apart in a competitive industry.
What Products and Services Does CNST Offer?
- Discover and develop innovative therapeutics for cancer treatment.
- Focus on addressing unmet medical needs in oncology.
- Conduct clinical trials for lead product candidates in various stages.
- Utilize epigenetic modulation to target cancers with abnormal gene expression.
- Collaborate with research institutions and industry partners to enhance drug development.
- Aim to improve patient outcomes through novel therapeutic approaches.
How Does CNST Make Money?
- Generate revenue through the development and commercialization of cancer therapeutics.
- Engage in partnerships and collaborations for research and development funding.
- Potentially earn royalties from product sales upon successful commercialization.
- Focus on advancing clinical trials to attract investment and funding.
- Leverage intellectual property to secure competitive advantages in the market.
What Industry Does CNST Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in personalized medicine and an increasing focus on oncology treatments. The global cancer therapeutics market is projected to grow significantly, reaching approximately $200 billion by 2026, fueled by rising cancer incidence rates and a growing demand for innovative therapies. Constellation Pharmaceuticals, with its focus on epigenetic approaches and targeted therapies, is well-positioned within this competitive landscape, competing with other biopharmaceutical companies that are also developing novel cancer treatments. The emphasis on addressing unmet medical needs in oncology aligns with broader industry trends, making Constellation a relevant player in this evolving market.
Who Are CNST's Key Customers?
- Healthcare providers and oncologists seeking innovative cancer treatments.
- Patients with cancers associated with abnormal gene expression or drug resistance.
- Pharmaceutical partners interested in collaboration for drug development.
- Investors looking for opportunities in the biopharmaceutical sector.
- Research institutions focused on cancer therapeutics and drug discovery.
Company Profile
Constellation Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Jigar Raythatha. CNST has traded publicly since 2018.
How Constellation Pharmaceuticals, Inc. Is Valued
Relative to its peer group, CNST's quantitative score of 47/100 is below the peer average of 58/100.
Key Financial Metrics
Return on equity for Constellation Pharmaceuticals, Inc. stands at -33.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.6%, showing how much profit it generates from its asset base. A current ratio of 14.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.8%, the inverse of the P/E and a quick read on earnings relative to price.
Earnings Track Record
Constellation Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 2.7% below estimates on average.
CNST Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Strong pipeline with multiple candidates in advanced clinical trials.
- Expertise in epigenetic modulation provides a competitive edge.
- Focus on unmet medical needs in oncology aligns with market demand.
- Experienced leadership team with a track record in biopharmaceuticals.
Bear Case
- Clinical-stage status means no current revenue generation.
- Dependence on successful trial outcomes for future growth.
- Limited market presence compared to larger biopharmaceutical companies.
- High operational costs associated with clinical trials and R&D.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CNST Latest News
No recent news available for CNST.
CNST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNST.
Price Targets
Wall Street price target analysis for CNST.
CNST MoonshotScore
What does this score mean?
The MoonshotScore rates CNST 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jigar Raythatha
CEO
Jigar Raythatha has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on oncology and rare diseases. Raythatha holds a degree in biomedical engineering and has been instrumental in driving innovation and growth at Constellation Pharmaceuticals.
Track Record: Under Jigar Raythatha's leadership, Constellation Pharmaceuticals has advanced multiple product candidates through clinical trials, positioning the company for potential market entry. His strategic vision has helped the company secure partnerships and funding to support its research initiatives.
Common Questions About CNST (Healthcare)
What does the AI Score mean for CNST?
CNST holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancers with unmet medical needs. The company is advancing multiple product …
What does Constellation Pharmaceuticals, Inc. do?
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer treatment. The company specializes in addressing serious unmet medical needs, particularly in oncology, with key product candidates like CPI-0610 and CPI-1205 currently in advanced clinical trials.
What do analysts say about CNST stock?
Analysts generally view Constellation Pharmaceuticals, Inc. as a high-risk, high-reward investment due to its clinical-stage status and the potential of its product pipeline. Key valuation metrics focus on the progress of its lead candidates in clinical trials, with expectations for significant market opportunities if successful.
What are the main risks for CNST?
The primary risks for Constellation Pharmaceuticals, Inc. include regulatory hurdles that could delay product approvals, high operational costs associated with clinical trials, and intense competition from other biopharmaceutical companies. Additionally, the potential for clinical trial failures poses a significant threat to the company's growth and valuation.
What are the key factors to evaluate for CNST?
Constellation Pharmaceuticals, Inc. (CNST) holds an AI score of 47/100 (low). is poised for growth driven by its innovative pipeline and strategic focus on unmet medical needs in oncology. Not financial advice.
How frequently does CNST data refresh on this page?
CNST's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CNST's recent stock price performance?
Constellation Pharmaceuticals, Inc. (CNST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline with multiple candidates in advanced clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNST overvalued or undervalued right now?
Constellation Pharmaceuticals, Inc. (CNST) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CNST before investing?
Before investing in Constellation Pharmaceuticals, Inc. (CNST), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change as new information becomes available.